A Brief Guide to Authors

Total Page:16

File Type:pdf, Size:1020Kb

A Brief Guide to Authors LATVIJAS ĶĪMIJAS ŽURNĀLS 2005, Nr. 4, 3.—269. lpp. A.M. El-Didamony1, M.A.F. El-Mosallamy1, A. Amin2, M. Mesherf1 SPECTROPHOTOMETRIC DETERMINATION OF BENZYDAMINE AND CHLORPHENOXAMINE HYDROCHLORIDES IN BULK AND PHARMACEUTICAL PREPARATIONS USING SULFOPHTHALEIN DYES 1Chemistry Department, Faculty of Science, Zagazig University, Zagazig, Egypt 2Chemistry Department, Faculty of Science, Benha University, Benha, Egypt Benzydamine hydrochloride (BZH), I is hydrochloride of N,N-dime- thyl-3-[1-phenylmethyl-1H-indazol-3-yl]oxy-1-propanamine (1-benzyl-3-(3-dime- methylaminopropoxy-1H-indazole, also named 1-benzyl-1H-indazol-3-yl 3-di- methylaminopropyl ether). It is a white crystalline powder, readily soluble in water, freely soluble in ethanol (95%), and in chloroform, practically insoluble in ether. N HCl N CH3 O N I CH 3 Benzydamine hydrochloride is a non-steroidal anti-inflammatory agent with analgesic, anti-exudative and local anesthetic activity. It is used topically on the skin in concentration of 3—5% in case of painful musculoskeletal and soft tissue disorder, also used as mouth wash or spray in concentration of 0.15% for relief of inflammatory conditions of mouth and throat. Chlorphenoxamine hydrochloride (II) is hydrochloride of 2-[1-(4-chlorophe- nyl)-1-phenylethoxy]-N,N-dimethylethanamine (2-[(p-chloro--methyl--phe- nylbenzyl)oxy]-N,N-dimethylethylamine, also named -dimethylaminoethyl (p-chloro--methyl-benzhydryl) ether). Cl O CH3 N CH3 HCl CH3 II Chlorphenoxamine hydrochloride is a white crystalline powder, readily so- luble in water, alcohol, and its aqueous solutions are stable. Chlorphenoxamine 263 hydrochloride possesses antimuscarinic and antihistaminic properties. It has been used in cases of nausea, vomiting and vertigo, and was formerly used in the symptomatic treatment of parkinsonism. It has also been used in hypers- ensitivity reaction. Chlorphenoxamine hydrochloride is not official in either the USP XXIV or the BP 2002. A few methods for the analysis of compounds I and II have been reported, including spectroscopic methods based on formation of coloured complexes [1—3]; other spectrophotometric methods that do not involve formation of coloured complexes [4—6]; IR spectroscopy [7], atomic absorption spectro- scopy [8], cation exchange [9], high-performance liquid [10, 11] and thin-layer chromatography [12], potentiometry [13], polarography [14]. The aim of the present work is to develop three simple, rapid and sensitive extraction spectrophotometric methods for the assay of benzydamine hydro- chloride and chlorphenoxamine hydrochloride. The methods are based on formation of ion-pair complexes of compounds I and II with dyestuffs such as bromophenol blue, bromocresol green, and bromocresol purple and subsequent extraction into chloroform under reaction conditions used. EXPERIMENTAL Apparatus. All the absorption spectra were taken using Shimadzu (UV-Visible 1601) spectrophotometer (Japan) with scanning speed of 400 nm/min, and band-width of 2.0 nm equipped with 10 mm matched quartz cells. The pH values of buffer solutions were measured using Jenway pH-meter (combined electrode). Reagents. All the chemicals used were of analytical or pharmaceutical grade, and water was twice-distilled. Pure benzydamine hydrochloride (BZH) (Tantum and Tantum rose) and chlorphenoxamine hydrochloride (CPH) (Allergics and Emeral), were obtained from Egyptian International Pharmaceutical Industrial Company (EPICO). Stock solutions of pure benzydamine hydrochloride and chlorphenoxamine hydrochloride (100 µgml–1) were prepared by dissolving 10 mg of pure drugs in water and filling up to the mark in a 100 ml volumetric flask with water. Working solutions of lower concentrations were prepared by serial dilution. Solutions of 5.010–4 moll–1 of bromocresol green (BCG), bromocresol purple (BCP) and bromophenol blue (BPB) (Aldrich) were prepared by dissolving an accurate weight of the dyes in few drops of acetone and then filling up to the mark with water in 100 ml volumetric flasks separately. A series of buffer solutions of CH3COONa–HCl (pH 1.99—5.2) and CH3COONa– CH3COOH (pH 3.42—5.89), and NaH2PO4–Na2HPO4 (pH 6.0—8.0) were prepared by the following standard methods. General procedures Benzydamine hydrochloride (I) Aliquot of compound I solution containing up to 2.0—28 μgml–1 of the drug was transferred into a series of 50 ml separating funnels, 2.0 ml of bromophenol blue, bromocresol green and bromocresol purple solutions (5.010–4 moll–1) were added followed by acetate buffer solution of pH = 3.1 (2.0 ml) when using bromophenol blue, pH = 3.3 (3.0 ml) when using bromocresol green and pH = 3.2 (2.0 ml) when using bromocresol purple. The formed ion pairs were extracted with 5.0 ml of CHCl3 under shaking for 3.0 min. The two phases were allowed to separate and the chloroform layer was dried by running through anhydrous sodium sulphate. The absorbance of the extracted solutions was measured at the corresponding max against extracted blank solution prepared similarly but without addition of the drug under study. Chlorphenoxamine hydrochloride (II) Aliquot of compound (II) solution containing up to 2.0—26 µgml–1 of the drug was transferred into a series of 50 ml separating funnels, 2.0 ml of bromophenol blue, bromocresol green or bromocresol purple solutions (5.010–4 moll–1) were added followed by acetate buffer solution of pH = 3.1 (2.5 ml) when using bromophenol blue, pH = 3.8 (2.0 ml) when using bromocresol green and pH = 3.2 (2.0 ml) when using bromocresol purple. The formed ion pairs were extracted with 5.0 ml of CHCl3 under shaking for 3.0 min. The two phases were allowed to 264 separate and the chloroform layer was dried by running through anhydrous sodium sulphate. The absorbance of the extracted solutions was measured at the corresponding max against extracted blank solution prepared similarly but without addition of the drug under study. A calibration graph was constructed for each drug and the concentration of unknown samples was deduced by using of the calibration graph. Procedure for Dosage Forms Bulk samples were prepared by weighing and pulverizing 20 tablets or capsules, or sachets and finding the average weight of each one. An amount of the sample equivalent to about 10 mg of the drug was weighed and dissolved in 100 ml of water, shaken well and filtered through a sintered glass crucible (G4). A 1.0 ml aliquot of the test solution was diluted to 100 ml in a volumetric flask. The drug content in this solution was obtained by applying the general procedure to aliquot containing 4.0 µgml–1 of the drug as described above and then followed by the standard addition method to confirm the obtained results. RESULTS AND DISCUSSION The nitrogenous drugs are present in positively charged protonated forms and anionic dyes of sulfophthalein group are present mainly in anionic form at pH 3.0. So when treated with an acid dye such as bromophenol blue, bromocresol green or bromocresol purple in acetate buffer solutions at pH ranged from 3.1 to 3.8, a yellow ion-pair complex which is extracted with chloroform is formed. The absorption spectra of the ion-pair complexes formed between benzydamine hydrochloride, chlorphenoxamine hydrochloride and each of sulfophthalein dyes (bromophenol blue, bromocresol green and bro- mocresol purple), were measured at 320—600 nm against a blank solution and are shown in Fig. 1, 2. The developed methods were applied to pharmaceutical preparations and the obtained results were evaluated statistically. 0.700 0.600 2 3 0.400 1 Absorbance, a.u. Absorbance, 0.200 0.000 320.0 400.0 500.0 600.0 Wavelength, , nm Fig. 1. Absorption spectra of benzydamine hydrochloride solution (4.0 gml–1) with dyestuff: 1 — bromophenol blue, 2 — bromocresol green, 3 — bromocresol purple Optimization of the reaction conditions The optimization of the reaction conditions of the proposed methods was carefully studied to achieve the complete reaction, highest sensitivity and maximum absorbance. Reaction conditions of formation of the ion-pair com- plexes were found by preliminary experiments varying pH of buffer solutions, nature of organic solvent, concentration of the sulfophthalein due and shaking time for the extraction of ion-pair complexes. 265 0.700 3 0.600 1 2 0.400 Absorbance, a.u. Absorbance, 0.200 0.000 335.0 350.0 400.0 450.0 500.0 555.0 Wavelength, , nm Fig. 2. Absorption spectra of chlorphenoxamine hydrochloride solution (4.0 gml–1) with dyestuff: 1 — bromophenol blue, 2 — bromocresol green, 3 — bromocresol purple Effect of pH The effect of pH was studied by extracting the coloured complex in the presence of various buffer solutions such as KCl–HCl (pH = 1.0—2.2), CH3COONa–HCl (pH = 1.99—6.0), CH3COONa–CH3COOH (pH = 3.7—5.8) and potassium hydrogen phthalate – HCl (pH = 2.2—3.6). The maximum colour intensity was developed and constant absorbance values were found in CH3COONa–HCl buffer solutions (see Fig. 3). It is evident that the absorbance of complexes with benzydamine hydrochloride was found to be maximal at pH 3.1, 3.3 and 3.2 using bromophenol blue, bromocresol green and bromocresol purple, respectively. As follows from Fig. 4, the absorbance of complexes with chlorphenoxamine hydrochloride is maximal at pH 3.1, 3.8 and 3.2 with bromophenol blue, bromocresol green and bromocresol purple, respectively. The optimum amount of buffer solution added to the aqueous layer of total volume of 5.0 ml was found to be 2.0 ml in case of benzydamine hydrochloride with bromophenol blue and bromocresol purple, and 3.0 ml with bromocresol green; 2.5 ml in case of chlorphenoxamine hydrochloride with bromophenol blue and 2.0 ml in case of chlorphenoxamine hydrochloride with bromocresol green and bromocresol purple that gave marginally the best results. Effect of the extracting solvent nature A number of organic solvents such as chloroform, dichloromethane, carbon tetrachloride, benzene and toluene were examined for extraction of the ion-pair complexes in order to provide an applicable extraction procedure.
Recommended publications
  • Wo 2010/075090 A2
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date 1 July 2010 (01.07.2010) WO 2010/075090 A2 (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every C07D 409/14 (2006.01) A61K 31/7028 (2006.01) kind of national protection available): AE, AG, AL, AM, C07D 409/12 (2006.01) A61P 11/06 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, (21) International Application Number: DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, PCT/US2009/068073 HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, (22) International Filing Date: KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, 15 December 2009 (15.12.2009) ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, (25) Filing Language: English SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, (26) Publication Language: English TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: (84) Designated States (unless otherwise indicated, for every 61/122,478 15 December 2008 (15.12.2008) US kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, (71) Applicant (for all designated States except US): AUS- ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, PEX PHARMACEUTICALS, INC.
    [Show full text]
  • Prohibited Substances List
    Prohibited Substances List This is the Equine Prohibited Substances List that was voted in at the FEI General Assembly in November 2009 alongside the new Equine Anti-Doping and Controlled Medication Regulations(EADCMR). Neither the List nor the EADCM Regulations are in current usage. Both come into effect on 1 January 2010. The current list of FEI prohibited substances remains in effect until 31 December 2009 and can be found at Annex II Vet Regs (11th edition) Changes in this List : Shaded row means that either removed or allowed at certain limits only SUBSTANCE ACTIVITY Banned Substances 1 Acebutolol Beta blocker 2 Acefylline Bronchodilator 3 Acemetacin NSAID 4 Acenocoumarol Anticoagulant 5 Acetanilid Analgesic/anti-pyretic 6 Acetohexamide Pancreatic stimulant 7 Acetominophen (Paracetamol) Analgesic/anti-pyretic 8 Acetophenazine Antipsychotic 9 Acetylmorphine Narcotic 10 Adinazolam Anxiolytic 11 Adiphenine Anti-spasmodic 12 Adrafinil Stimulant 13 Adrenaline Stimulant 14 Adrenochrome Haemostatic 15 Alclofenac NSAID 16 Alcuronium Muscle relaxant 17 Aldosterone Hormone 18 Alfentanil Narcotic 19 Allopurinol Xanthine oxidase inhibitor (anti-hyperuricaemia) 20 Almotriptan 5 HT agonist (anti-migraine) 21 Alphadolone acetate Neurosteriod 22 Alphaprodine Opiod analgesic 23 Alpidem Anxiolytic 24 Alprazolam Anxiolytic 25 Alprenolol Beta blocker 26 Althesin IV anaesthetic 27 Althiazide Diuretic 28 Altrenogest (in males and gelidngs) Oestrus suppression 29 Alverine Antispasmodic 30 Amantadine Dopaminergic 31 Ambenonium Cholinesterase inhibition 32 Ambucetamide Antispasmodic 33 Amethocaine Local anaesthetic 34 Amfepramone Stimulant 35 Amfetaminil Stimulant 36 Amidephrine Vasoconstrictor 37 Amiloride Diuretic 1 Prohibited Substances List This is the Equine Prohibited Substances List that was voted in at the FEI General Assembly in November 2009 alongside the new Equine Anti-Doping and Controlled Medication Regulations(EADCMR).
    [Show full text]
  • (19) United States (12) Patent Application Publication (10) Pub
    US 20130210835A1 (19) United States (12) Patent Application Publication (10) Pub. N0.2 US 2013/0210835 A1 Mitchell (43) Pub. Date: Aug. 15, 2013 (54) PHARMACEUTICAL COMPOSITIONS Publication Classi?cation (75) Inventor: Odes W. Mitchell; Arlington, TX (U S) (51) Int. Cl. A61K31/137 (2006.01) _ A611; 31/4402 (2006.01) (73) Ass1gnee: GM PHARMACEUTICAL, INC, A61K 31/485 (200601) Arhngton, TX (Us) A611; 31/09 (2006.01) _ A611; 31/495 (2006.01) (21) App1.No.. 13/703,584 A61K31/505 (200601) 22 PCT P1 d: J .13 2011 (52) us Cl ( ) 1e “n ’ CPC ........... .. A611; 31/137 (2013.01); A611;31/495 (86) PCT NO. PCT/“11,4031 (2013.01); A611;31/505 (2013.01); A611; 31/485 (2013.01); A611; 31/09 (2013.01); § 371 (0)0). A611;31/4402 (2013.01) (2), (4) Date: Feb- 2, 2013 USPC .... .. 514/255.04; 564/355; 514/653; 544/396; 544/332; 514/275; 546/74; 514/289; 514/282; Related US. Application Data 514657; 514652 (60) Provisional application No. 61/354,061; ?led on Jun. (57) ABSTRACT 11; 2010; provisional application No. 61/354,057; A composition of an antitussive; a decongestant; or an anti ?led on Jun. 11; 2010; provisional application No. histamine to treat respiratory and oral pharyngeal congestion 61/354,053; ?led on Jun. 11,2010. and related symptoms in a patient. US 2013/0210835 A1 Aug. 15,2013 PHARMACEUTICAL COMPOSITIONS mucus build-up to clear congestion in the air passages. Symp toms due to allergies or allergens are often treated With an CROSS-REFERENCES TO RELATED antihistamine.
    [Show full text]
  • BMJ Open Is Committed to Open Peer Review. As Part of This Commitment We Make the Peer Review History of Every Article We Publish Publicly Available
    BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available. When an article is published we post the peer reviewers’ comments and the authors’ responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to. The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript. BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (http://bmjopen.bmj.com). If you have any questions on BMJ Open’s open peer review process please email [email protected] BMJ Open Pediatric drug utilization in the Western Pacific region: Australia, Japan, South Korea, Hong Kong and Taiwan Journal: BMJ Open ManuscriptFor ID peerbmjopen-2019-032426 review only Article Type: Research Date Submitted by the 27-Jun-2019 Author: Complete List of Authors: Brauer, Ruth; University College London, Research Department of Practice and Policy, School of Pharmacy Wong, Ian; University College London, Research Department of Practice and Policy, School of Pharmacy; University of Hong Kong, Centre for Safe Medication Practice and Research, Department
    [Show full text]
  • Vr Meds Ex01 3B 0825S Coding Manual Supplement Page 1
    vr_meds_ex01_3b_0825s Coding Manual Supplement MEDNAME OTHER_CODE ATC_CODE SYSTEM THER_GP PHRM_GP CHEM_GP SODIUM FLUORIDE A12CD01 A01AA01 A A01 A01A A01AA SODIUM MONOFLUOROPHOSPHATE A12CD02 A01AA02 A A01 A01A A01AA HYDROGEN PEROXIDE D08AX01 A01AB02 A A01 A01A A01AB HYDROGEN PEROXIDE S02AA06 A01AB02 A A01 A01A A01AB CHLORHEXIDINE B05CA02 A01AB03 A A01 A01A A01AB CHLORHEXIDINE D08AC02 A01AB03 A A01 A01A A01AB CHLORHEXIDINE D09AA12 A01AB03 A A01 A01A A01AB CHLORHEXIDINE R02AA05 A01AB03 A A01 A01A A01AB CHLORHEXIDINE S01AX09 A01AB03 A A01 A01A A01AB CHLORHEXIDINE S02AA09 A01AB03 A A01 A01A A01AB CHLORHEXIDINE S03AA04 A01AB03 A A01 A01A A01AB AMPHOTERICIN B A07AA07 A01AB04 A A01 A01A A01AB AMPHOTERICIN B G01AA03 A01AB04 A A01 A01A A01AB AMPHOTERICIN B J02AA01 A01AB04 A A01 A01A A01AB POLYNOXYLIN D01AE05 A01AB05 A A01 A01A A01AB OXYQUINOLINE D08AH03 A01AB07 A A01 A01A A01AB OXYQUINOLINE G01AC30 A01AB07 A A01 A01A A01AB OXYQUINOLINE R02AA14 A01AB07 A A01 A01A A01AB NEOMYCIN A07AA01 A01AB08 A A01 A01A A01AB NEOMYCIN B05CA09 A01AB08 A A01 A01A A01AB NEOMYCIN D06AX04 A01AB08 A A01 A01A A01AB NEOMYCIN J01GB05 A01AB08 A A01 A01A A01AB NEOMYCIN R02AB01 A01AB08 A A01 A01A A01AB NEOMYCIN S01AA03 A01AB08 A A01 A01A A01AB NEOMYCIN S02AA07 A01AB08 A A01 A01A A01AB NEOMYCIN S03AA01 A01AB08 A A01 A01A A01AB MICONAZOLE A07AC01 A01AB09 A A01 A01A A01AB MICONAZOLE D01AC02 A01AB09 A A01 A01A A01AB MICONAZOLE G01AF04 A01AB09 A A01 A01A A01AB MICONAZOLE J02AB01 A01AB09 A A01 A01A A01AB MICONAZOLE S02AA13 A01AB09 A A01 A01A A01AB NATAMYCIN A07AA03 A01AB10 A A01
    [Show full text]
  • Biperiden and Chlorphenoxamine) in Various Dosage Forms by Spectrophotometry
    International Journal of Chemical and Analytical Science ISSN: 0976-1206 Research Article www.ijcas.info Simultaneous Determination of some anticholinergic drugs (Biperiden and Chlorphenoxamine) in Various Dosage forms by Spectrophotometry Issa FAA1, EL-Helbawy SM2 and Abed EL- Magied AM2* 1Chemistry Department, faculty of science, Menoufia University 2Medico-Legal organization, Ministry of Justice, Cairo, Egypt Simple and rapid spectrophotometric procedures were established for quantization of biperiden hydrochloride (BPN) and chlorphenoxamine hydrochloride (CPA). The procedures are based on the reaction between the examined drugs BPN and CPA and picric acid (I), alizarin (II), bromothymol blue (III) and chlorophenol red (IV) producing ion-associates which can be measured at the optimum wavelength. The optimization of the reaction conditions was investigated. Beer’s law is obeyed in the concentration ranges 58.8 –166.4 µgml−1. The molar absorptivity, Sandell sensitivity are also calculated. The correlation coefficient was ≥0.9996 (n = 6) with a relative standard deviation (R.S.D.) ≤1.35 for four determinations. The methods are successfully applied to determine of BPN and CPA in pharmaceutical formulations. Keywords: Spectrophotometry, Ion-Associates, Drugs, Biperiden, Chlorphenoxamine INTRODUCTION MATERIALS AND METHODS Biperiden hydrochloride (BPN) is α-Bicyclo [2.2.1] hept–5–en– Apparatus: The spectral measurements were carried out by 2–yl-α-phenyl–1–piperidinepropanol. Chlorphenoxamine using U.V-visible spectrophotometer (Helios Alpha) with a hydrochloride (CPA) is 2-[1-(4-Chlorophenyl)-1–phenyl- 10mm quartz cell, optical path length was used. phenylethoxy]-N, N-dimethylethanamine. They are a weak peripheral anticholinergic[1,2] Agent. It has, therefore, some Reagents: Picric acid 2,4,6 tri nitro phenol (I), Alizarin 1,2 di antisecretory, antispasmodic, mydriatic and antihistaminic hydroxy anthraquinone (II), bromothymol blue 3,3 effects.
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]
  • 2 12/ 35 74Al
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date 22 March 2012 (22.03.2012) 2 12/ 35 74 Al (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 9/16 (2006.01) A61K 9/51 (2006.01) kind of national protection available): AE, AG, AL, AM, A61K 9/14 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, (21) International Application Number: DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, PCT/EP201 1/065959 HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, (22) International Filing Date: KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, 14 September 201 1 (14.09.201 1) ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, (25) Filing Language: English RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, (26) Publication Language: English TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: 61/382,653 14 September 2010 (14.09.2010) US (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, (71) Applicant (for all designated States except US): GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, NANOLOGICA AB [SE/SE]; P.O Box 8182, S-104 20 ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, Stockholm (SE).
    [Show full text]
  • Prescription Medications, Drugs, Herbs & Chemicals Associated With
    Prescription Medications, Drugs, Herbs & Chemicals Associated with Tinnitus American Tinnitus Association Prescription Medications, Drugs, Herbs & Chemicals Associated with Tinnitus All rights reserved. No part of this publication may be reproduced, stored in a retrieval system or transmitted in any form, or by any means, without the prior written permission of the American Tinnitus Association. ©2013 American Tinnitus Association Prescription Medications, Drugs, Herbs & Chemicals Associated with Tinnitus American Tinnitus Association This document is to be utilized as a conversation tool with your health care provider and is by no means a “complete” listing. Anyone reading this list of ototoxic drugs is strongly advised NOT to discontinue taking any prescribed medication without first contacting the prescribing physician. Just because a drug is listed does not mean that you will automatically get tinnitus, or exacerbate exisiting tinnitus, if you take it. A few will, but many will not. Whether or not you eperience tinnitus after taking one of the listed drugs or herbals, or after being exposed to one of the listed chemicals, depends on many factors ‐ such as your own body chemistry, your sensitivity to drugs, the dose you take, or the length of time you take the drug. It is important to note that there may be drugs NOT listed here that could still cause tinnitus. Although this list is one of the most complete listings of drugs associated with tinnitus, no list of this kind can ever be totally complete – therefore use it as a guide and resource, but do not take it as the final word. The drug brand name is italicized and is followed by the generic drug name in bold.
    [Show full text]
  • European Patent Office
    Europäisches Patentamt *EP001021204B1* (19) European Patent Office Office européen des brevets (11) EP 1 021 204 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.7: A61K 47/32, A61L 25/00 of the grant of the patent: 28.12.2005 Bulletin 2005/52 (86) International application number: PCT/US1998/020091 (21) Application number: 98949505.6 (87) International publication number: (22) Date of filing: 25.09.1998 WO 1999/015210 (01.04.1999 Gazette 1999/13) (54) BIOADHESIVE COMPOSITIONS AND METHODS FOR TOPICAL ADMINISTRATION OF ACTIVE AGENTS BIOLOGISCHE KLEBER UND VERFAHREN ZUR TOPISCHEN VERABREICHUNG VON WIRKSTOFFEN COMPOSITIONS BIOADHESIVES ET METHODES D’ADMINISTRATION LOCALE D’AGENTS ACTIFS (84) Designated Contracting States: • HOUZE, David AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU Miami, FL 33186 (US) MC NL PT SE • KANIOS, David Miami, FL 33196 (US) (30) Priority: 26.09.1997 US 61155 P (74) Representative: Isenbruck, Günter (43) Date of publication of application: Isenbruck, Bösl, Hörschler, Wichmann, Huhn 26.07.2000 Bulletin 2000/30 Patentanwälte Theodor-Heuss-Anlage 12 (73) Proprietor: NOVEN PHARMACEUTICALS, INC. 68165 Mannheim (DE) Miami, FL 33186 (US) (56) References cited: (72) Inventors: FR-A- 2 532 546 GB-A- 1 050 070 • MANTELLE, Juan GB-A- 2 046 773 US-A- 4 593 053 Miami, FL 33176 (US) US-A- 5 656 286 Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted.
    [Show full text]
  • Final1-Aritmo-Final-Report-V2-0Final.Pdf
    ARITMO Final Report PROJECT FINAL REPORT Grant Agreement number: 241679 Project acronym: ARITMO Project title: Arrhythmogenic potential of drugs Funding Scheme: Small or Medium-Scale Focused Research Project Period covered: from 1st January 2010 to 30th June 2013 Name of the scientific representative of the project's co-ordinator, Title and Organisation: Prof. Miriam CJM Sturkenboom, Erasmus Universitair Medisch Centrum Rotterdam Tel: +31 10 704 4126 Fax: +31 10 704 4722 E-mail: [email protected] Project website1 address: www.aritmo-project.org 1 The home page of the website should contain the generic European flag and the FP7 logo which are available in electronic format at the Europa website (logo of the European flag: http://europa.eu/abc/symbols/emblem/index_en.htm ; logo of the 7th FP: http://ec.europa.eu/research/fp7/index_en.cfm?pg=logos). The area of activity of the project should also be mentioned. © Copyright 2013 ARITMO Consortium 1 ARITMO Final Report Table of contents Table of contents ................................................................................................................................................................. 2 1. Final publishable summary report ................................................................................................................................ 3 1.1 Executive summary ................................................................................................................................................. 3 1.2 Description of project context and
    [Show full text]
  • 5- Normal Phase High Performance Liquid Chromatographic Determination of Chlorphenoxamine Hydrochloride, Caffeine and 8-Chlorotheophylline
    5- NORMAL PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHIC DETERMINATION OF CHLORPHENOXAMINE HYDROCHLORIDE, CAFFEINE AND 8-CHLOROTHEOPHYLLINE Y. M. Dessouky, H. H. Hassanein, M. Abdul-Azim Mohammad* and R. S. Hanafy** Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Cairo University, Kasrel-Aiani, 11562, Cairo, Egypt. Received:14-3-2004 Accepted:16-5-2004 Abstract: INTRODUCTION An isocratic, rapid and reproducible high performance liquid chromatographic (HPLC) Chlorphenoxamine hydrochloride (CPHX), [I] method for quantitative determination of chlor- is a histamine H1- receptor antagonist with anti- phenoxamine hydrochloride (CPHX), caffeine muscarinic properties 1. Caffeine (CAFF), [2] is a (CAFF) and 8-chlorotheophylline (CTHE) has been xanthine derivative with CNS stimulant activity 1-3. adopted. The optimal conditions for separation and 8-Chlorotheophylline (CTHE) [3] is also a xanthine quantitative determination of these compounds derivative that forms with dipenhydramine a were a normal phase mode chromatography and compound named dimenhydrinate that is widely isocratic elution at ambient temperature. A silica used for alleviation of motion sickness 1-3. column and a mobile phase consisted of ethyl Combination of the three drugs is known 1,4. acetate - methanol (50:50 v/v) / triethylamine pH 9, CPHX was determined by titrimetric 2, have been used at a flow rate of 1 ml min-1. The electrochemical 5, spectrophotometric 6-8, derivative components of column effluent were monitored by spectrophotometric 9,10, derivative ratio spectro- 11 11 UV detector at 254 nm. The retention times (tR) for photometric , chemometric and spectro- CPHX, CAFF and CTHE were 6.15, 4.23 and 2.97 fluorimetric 12 methods. Chromatographic methods min, respectively.
    [Show full text]